News | January 07, 2023
KIMS invests further in Sarvejana Healthcare
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
The new eye hospital in Vashi is ASG’s second in the Mumbai Metropolitan Region (MMR) and the sixth in Maharashtra
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The laboratory is equipped to perform high-volume diagnostic testing services
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
Subscribe To Our Newsletter & Stay Updated
